ISSN (print) 1997-6933     ISSN (online) 2500-2139

LYMPHOID TUMORS

Sergei Vyacheslavovich Semochkin, E.I. Zhelnova, V.I. Kazey, A.V. Cherkasova, A.G. Nikiforova, N.F. Frolova, E.A. Baryakh, K.V. Yatskov, E.A. Karimova, O.N. Kotenko, E.N. Misyurina
360-369
The Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination as Induction Therapy in Patients with Multiple Myeloma Complicated by the End-Stage Renal Disease
1 October 2024
Irina Germanovna Rekhtina, V.A. Khyshova, A.M. Kovrigina, M.A. Silaev, L.P. Mendeleeva
370-375
Sarcoid-like Pulmonary Lesion in a Female Patient with Multiple Myeloma and Systemic AL Amyloidosis Treated with Daratumumab: A Case of Spontaneous Regression of Lung Tissue Changes upon Drug Withdrawal
1 October 2024
Olesya Nikolaevna Selyutina, E.Yu. Zlatnik, N.K. Guskova, I.A. Novikova, I.B. Lysenko, A.B. Sagakyants, T.F. Pushkareva, L.Yu. Vladimirova
376-383
Bone Marrow Lymphocyte Subpopulation in Chronic Lymphocytic Leukemia Patients with Different Responses to Chemotherapy
1 October 2024
I.S. Dolgopolov, Maksim Yurevich Rykov
384-389
The Impact of Routing on a Speedy Diagnosis of Acute Leukemia in Children: Results of a Regional Study
1 October 2024
Alena Yurevna Terekhova, N.A. Falaleeva, A.B. Galitsyna, A.M. Chelmakov, A.A. Vovchenko, N.A. Riabikina, A.A. Danilenko, T. I. Bogatyreva
225-236
Treatment Outcomes in Primary Mediastinal Large B-Cell Lymphoma. Experience of the AF Tsyb Medical Radiological Research Center (Obninsk)
1 July 2024
Olga Vladislavovna Pirogova, O.V. Kudyasheva, M.V. Chernous, M.A. Gorodnova, D.K. Lamden, K.A. Novitskaya, A.G. Smirnova, A.V. Yakovleva, V.A. Ionin, A.M. Ananin, I.S. Moiseev, A.D. Kulagin
237-245
Impact of Cardiac Disease on Prognosis in Patients with Systemic AL Amyloidosis
1 July 2024
Aleksander Sergeevich Luchinin, A.A. Semenova, S.V. Semochkin
246-255
Multiple Myeloma: Simulation of Therapy Scenarios Using the Monte Carlo Method
1 July 2024
Anna Mikhailovna Sergeeva, V.L. Surin, Yu.A. Chabaeva, A.A. Kraizman, M.V. Solovev, S.M. Kulikov, L.P. Mendeleeva
256-265
KRAS/NRAS Gene Mutations and the Efficacy of Bortezomib-Based Triplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
1 July 2024
Elena Viktorovna Vaneeva, V.A. Rosin, D.A. Dyakonov, N.V. Glubokovskikh
266-272
The Prognostic Value of Cytotoxic CD8-Positive Т-Lymphocytes of the Reactive Tumor Microenvironment in Diffuse Large B-Cell Lymphoma
1 July 2024
Evgeniya Viktorovna Paramonova, Yu.I. Klyuchagina, M.Yu. Kichigina, D.N. Tupitsyna, V.O. Shpirko, A.V. Arakelyan, A.A. Semenova, E.A. Demina, O.P. Trofimova, A.S. Subbotin, M.A. Senchenko, G.S. Tumyan
27-36
Treatment of Patients with Local Stages of Newly Diagnosed Classical Hodgkin Lymphoma: A Literature Review, Current Approaches, and Our Own Experience
17 May 2024
Nadezhda Viktorovna Kurkina, E.A. Repina, E.I. Gorshenina, V.O. Kurkina, P.V. Volkova, A.A. Repin
37-42
Ibrutinib in Chronic Lymphocytic Leukemia Therapy for High- and Very-High-Risk Patients over 60 Years of Age
17 May 2024
Yana Yurevna Shebunyaeva
141-153
The Role of Polymorphic Variants of Р450 Cytochrome Genes as well as Genes GSTP1 and MDR1 in Toxic Complications of Program Drug Chemotherapy for Classical Hodgkin Lymphoma
1 April 2024
Igor Alekseevich Olkhovskii
154-165
Diagnostic Potential of Regulatory Non-Coding Protein RNAs in Chronic Lymphocytic Leukemia
1 April 2024
Maksim Sergeevich Minaev
166-172
CD20-Positive B-Lymphocytes in the Reactive Tumor Microenvironment as an Independent Immunohistochemical Prognostic Factor in Nodular Sclerosis Classical Hodgkin Lymphoma
1 April 2024
Marat Albertovich Mingalimov
173-179
Therapy Optimization in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Efficacy and Safety of the R-SD-EPOCH ± HDMTX Program Under Single-Center Non-Randomized Prospective Clinical Trial (Preliminary Results)
1 April 2024
Ekaterina Sergeevna Nesterova, N.A. Severina, B.V. Biderman, A.B. Sudarikov, A.M. Kovrigina, T.N. Obukhova, Ya.K. Mangasarova, S.M. Kulikov, E.E. Zvonkov, E.N. Parovichnikova, V.G. Savchenko
80-87
Identification of Somatic Mutations in EZH2 Gene and Assessment of Their Prognostic Value in Follicular Lymphoma Grades 1–3А
20 February 2024
Mariya Sergeevna Voitko, T.I. Pospelova, I.N. Nechunaeva, Ya.Yu. Shebunyaeva
192-199
Long-Term Results of Classical Hodgkin’s Lymphoma Treatment in Real-World Clinical Practice: Experience of Novosibirsk Hematological Unit
20 February 2024
Svetlana Yurevna Smirnova, E.E. Nikulina, N.G. Gabeeva, D.A. Koroleva, S.A. Tatarnikova, A.K. Smol’yaninova, E.G. Gemdzhian, E.E. Zvonkov, A.B. Sudarikov
200-208
Plasma Cell-Free DNA in Patients with Diffuse Large B-Cell and B-Cell High-Grade (Double Hit/Triple Hit) Lymphomas
20 February 2024
Nadezhda Viktorovna Kurkina, E.A. Repina, P.V. Volkova, A.A. Repin
209-212
Ibrutinib Efficacy in First-Line Therapy of High-Risk Patients Vs. Second- and Third-Line Therapies of Resistant Chronic Lymphocytic Leukemia
20 February 2024
Elizaveta Vyacheslavovna Kleina, S.V. Voloshin, Yu.S. Vokueva, O.D. Petukhova, E.V. Motyko, M.P. Bakai, D.V. Kustova, A.N. Kirienko, S.Yu. Linnikov, E.V. Karyagina, O.S. Uspenskaya, I.S. Zyuzgin, S.V. Sidorkevich, I.S. Martynkevich
213-226
The Prognostic Role of Genetic Aberrations in Mantle Cell Lymphoma: A Literature Review and Clinical Experience
20 February 2024